Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

This phase II trial tests how well lovastatin and pembrolizumab work in treating patients with head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Lovastatin is a drug used to lower the amount of cholesterol in the blood and may also cause tumor cell death. In addition, studies have shown that lovastatin may make the tumor cells more sensitive to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system att

Trial Details

NCT ID

NCT06636734

Phase

PHASE2

Sponsor

Emory University

Status

RECRUITING

Cancer Type

HPV Positive Head and Neck Cancer

Interventions

Biospecimen Collection
Computed Tomography
Lovastatin
Magnetic Resonance Imaging
Pembrolizumab
Positron Emission Tomography

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

Adult patients, male or female, aged ≥ 18, able to provide informed consent
Subjects with pathologically proven, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) involving the oral cavity, oropharynx, l…
PD-L1 combined positive score (CPS) ≥ 1 (i.e., must be a candidate for treatment with pembrolizumab alone)
Patients must not be under consideration for salvage surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →